image
Healthcare - Medical - Devices - NASDAQ - US
$ 256.23
4.47 %
$ 18 B
Market Cap
44.41
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PODD stock under the worst case scenario is HIDDEN Compared to the current market price of 256 USD, Insulet Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PODD stock under the base case scenario is HIDDEN Compared to the current market price of 256 USD, Insulet Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PODD stock under the best case scenario is HIDDEN Compared to the current market price of 256 USD, Insulet Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PODD

image
$290.0$290.0$280.0$280.0$270.0$270.0$260.0$260.0$250.0$250.0$240.0$240.0$230.0$230.0$220.0$220.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
2.07 B REVENUE
22.07%
309 M OPERATING INCOME
40.41%
418 M NET INCOME
102.76%
430 M OPERATING CASH FLOW
195.33%
-146 M INVESTING CASH FLOW
-22.45%
-28.1 M FINANCING CASH FLOW
-106.62%
598 M REVENUE
60.36%
109 M OPERATING INCOME
24.06%
101 M NET INCOME
29.94%
148 M OPERATING CASH FLOW
49.95%
-68 M INVESTING CASH FLOW
-132.08%
-20.9 M FINANCING CASH FLOW
-267.95%
Balance Sheet Insulet Corporation
image
Current Assets 1.89 B
Cash & Short-Term Investments 953 M
Receivables 366 M
Other Current Assets 572 M
Non-Current Assets 1.2 B
Long-Term Investments 0
PP&E 723 M
Other Non-Current Assets 473 M
30.88 %11.84 %18.54 %23.42 %15.33 %Total Assets$3.1b
Current Liabilities 528 M
Accounts Payable 19.8 M
Short-Term Debt 83.8 M
Other Current Liabilities 425 M
Non-Current Liabilities 1.35 B
Long-Term Debt 0
Other Non-Current Liabilities 1.35 B
4.47 %22.64 %71.84 %Total Liabilities$1.9b
EFFICIENCY
Earnings Waterfall Insulet Corporation
image
Revenue 2.07 B
Cost Of Revenue 626 M
Gross Profit 1.45 B
Operating Expenses 1.14 B
Operating Income 309 M
Other Expenses -109 M
Net Income 418 M
3b3b2b2b2b2b1b1b500m500m002b(626m)1b(1b)309m109m418mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
69.79% GROSS MARGIN
69.79%
14.91% OPERATING MARGIN
14.91%
20.19% NET MARGIN
20.19%
34.52% ROE
34.52%
13.55% ROA
13.55%
16.28% ROIC
16.28%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Insulet Corporation
image
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 418 M
Depreciation & Amortization 80.8 M
Capital Expenditures -125 M
Stock-Based Compensation 69.3 M
Change in Working Capital 0
Others -1.2 M
Free Cash Flow 305 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Insulet Corporation
image
Wall Street analysts predict an average 1-year price target for PODD of $249 , with forecasts ranging from a low of $200 to a high of $300 .
PODD Lowest Price Target Wall Street Target
200 USD -21.95%
PODD Average Price Target Wall Street Target
249 USD -2.90%
PODD Highest Price Target Wall Street Target
300 USD 17.08%
Price
Max Price Target
Min Price Target
Average Price Target
300300280280260260240240220220200200180180160160May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Insulet Corporation
image
Sold
0-3 MONTHS
3.97 M USD 2
3-6 MONTHS
1.56 M USD 3
6-9 MONTHS
4.14 M USD 5
9-12 MONTHS
2.7 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
20.6 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025 ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Rela. businesswire.com - 1 week ago
Insulet Gains 62.9% in a Year: What's Driving the Stock? PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning. zacks.com - 3 weeks ago
PODD Stock Gains Following the Launch of Omnipod 5 in Australia Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility. zacks.com - 3 weeks ago
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5 Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD. zacks.com - 3 weeks ago
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections ACTON, Mass.--(BUSINESS WIRE)--Insulet's RADIANT trial demonstrates meaningful glycemic improvements with Omnipod 5 AID following direct transition from multiple daily injections. businesswire.com - 4 weeks ago
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions. zacks.com - 4 weeks ago
Insulet Announces Pricing of Senior Notes Due 2033 ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”). The Notes will bear interest at an annual rate of 6.50% and will mature on April 1, 2033, unless earlier redeemed or repurchased. The closing of the private placement is expected to occur on March 20, 2025, subject to customary closing conditions. businesswire.com - 4 weeks ago
Insulet Announces Proposed Financing Transactions ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”) in a private placement. The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash fr. businesswire.com - 4 weeks ago
Insulet Leans Bullish (Technical Analysis) PODD exhibits bullish price action with a series of higher highs and lows, trading above its upward sloping 30-week EMA since August 2024. Momentum is long-term bullish but short-term bearish, with the PPO line above zero indicating positive long-term momentum. Volume analysis shows neutral to slightly bullish accumulation by institutional investors, with recent high volume supporting bullish price action. seekingalpha.com - 4 weeks ago
Insulet to Host Investor Day on June 5, 2025 ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's lea. businesswire.com - 1 month ago
Insulet Sales Keep Rising Insulet Corporation (PODD) continues its strong sales and growth trend. fxempire.com - 1 month ago
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst On Thursday, Insulet Corporation PODD reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02. benzinga.com - 1 month ago
8. Profile Summary

Insulet Corporation PODD

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 18 B
Dividend Yield 0.00%
Description Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Contact 100 Nagog Park, Acton, MA, 01720 https://www.insulet.com
IPO Date May 15, 2007
Employees 3900
Officers Mr. Prem Singh Senior Vice President of Global Operations Ms. Angela Geryak Wiczek Senior Director of Corporate Communications Mr. John Wodick Kapples J.D. Senior Vice President & General Counsel Ms. Laetitia Cousin Senior Vice President of Regulatory Affairs, Quality Assurance & Compliance Mr. Eric Benjamin Executive Vice President, Chief Product & Customer Experience Officer June Lazaroff Senior Director of Investor Relations Ms. Ana Maria Chadwick Executive Vice President, Chief Financial Officer & Treasurer Dr. James R. Hollingshead Ph.D. President, Chief Executive Officer & Director Mr. Amit Guliani Interim Chief Technology Officer & Group Vice President of Customer-Facing Software Engineering Ms. Lauren Budden Group Vice President, Chief Accounting Officer & Controller